That led to a January 2012 agreement with the Justice Department that cited the company for submitting false data to the FDA and barred the company from manufacturing drugs for the American market at those facilities until they could meet U.S. standards. "The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles approximately less than 1mm in size)," Ranbaxy's U.S. subsidiary said in a statement on its website. " A full list of the recalled lots can be found at http://ranbaxyusa.com/images/a.pdf Ranbaxy said its action was taken "with the full knowledge" of the U.S. Food and Drug Administration, which granted the company its approval to manufacture the drug at a plant in New Jersey in 2011. -- A manufacturer of a popular cholesterol-reducing medication has recalled more than 40 batches of the product after warning that they may contain small particles of glass. "Ranbaxy is proactively recalling the drug product lots out of an abundance of caution, and in keeping the safety of our customers in mind.